Neomi Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.40 M
as on 27-07-2024
- Paid Up Capital ₹ 0.40 M
as on 27-07-2024
- Company Age 8 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 143.00%
(FY 2023)
- Profit 546.43%
(FY 2023)
- Ebitda 75.78%
(FY 2023)
- Net Worth 176.94%
(FY 2023)
- Total Assets 90.78%
(FY 2023)
About Neomi Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.40 M and a paid-up capital of Rs 0.40 M, as per Ministry of Corporate Affairs (MCA) records.
Jetal Sota and Amit Sota serve as directors at the Company.
- CIN/LLPIN
U46497MH2016PTC272811
- Company No.
272811
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Feb 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Neomi Pharmaceuticals Private Limited offer?
Neomi Pharmaceuticals Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Malaria Medicine, TB, Tumor & Cancer Drugs, Anti Cancer Injection, Anti Cancer Medicines, Antibacterial Drugs.
Who are the key members and board of directors at Neomi Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jetal Sota  | Director | 06-Feb-2016 | Current |
| Amit Sota | Director | 06-Feb-2016 | Current |
Financial Performance of Neomi Pharmaceuticals.
Neomi Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 143% increase. The company also saw a substantial improvement in profitability, with a 546.43% increase in profit. The company's net worth Soared by an impressive increase of 176.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Neomi Pharmaceuticals?
In 2023, Neomi Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Neomi Pharmaceuticals?
Unlock and access historical data on people associated with Neomi Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neomi Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neomi Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
